Abstract
Background: X-linked partial androgen insensitivity syndrome (PAIS) causes under-virilization at all stages of development. In two thirds of males, this results in micropenis. Dihydrotestosterone (DHT) is a potent androgen that is critical for male genital development, which when applied topically, has been shown to increase penile length with micropenis of varying etiologies. We present the first case series using topical DHT gel to treat micropenis in 46,XY males with PAIS, before, during, and after puberty.
Methods: Three related 46,XY males with confirmed p.L712F androgen receptor mutations exhibited varying degrees of micropenis post-surgical correction. They were of pre-pubertal, peri-pubertal and adult ages, respectively. Following baseline clinical and laboratory assessments all completed a 4-month course of daily DHT gel 2.5% (androstanolone) topically to penis (0.3 mg/kg body weight), with monitoring for adverse effects. Primary outcome was change in stretched penile length (SPL) following treatment.
Results: Mixed results were obtained following topical DHT therapy. In the pre- and peri- pubertal patients, SPL changed from 2.5 cm to 3.5 cm (+40%), and 3.5 cm to 5.7 cm (+63%), respectively. In the adult patient with 1 year of prior high-dose weekly testosterone therapy, no additional change in SPL was seen. No adverse effects of topical DHT were reported or observed throughout the 4 months of treatment.
Conclusions: Topical DHT treatment appears to be a safe and well-tolerated method of virilising micropenis both prior to and during puberty in children with PAIS. Questions remain about long-term outcomes into adulthood, and efficacy in adults with prior lengthy exposure to high-dose testosterone.
Acknowledgments
The authors wish to thank the participants and their families for their forbearance and generous participation.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Murashima A, Kishigami S, Thomson A, Yamada G. Androgens and mammalian male reproductive tract development. Biochimica et Biophysica Acta 2015;1849:163–70.10.1016/j.bbagrm.2014.05.020Search in Google Scholar
2. Kumanov P, Robeva R, Tomova A. Prevalence of micropenis among boys from different regions of Bulgaria. J Pediatr Endocrinol Metab 2007;20:791–5.10.1515/JPEM.2007.20.7.791Search in Google Scholar
3. Gottlieb B, Pinsky L, Beitel LK, Trifiro M. Androgen insensitivity. Am J Med Genet 1999;89:210–7.10.1002/(SICI)1096-8628(19991229)89:4<210::AID-AJMG5>3.0.CO;2-PSearch in Google Scholar
4. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations database:2012 update. Hum Mutat 2012;33:887–94.10.1002/humu.22046Search in Google Scholar
5. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, et al. Androgen insensitivity syndrome. Lancet 2012;380:1419–28.10.1016/S0140-6736(12)60071-3Search in Google Scholar
6. Holterhus PM, Sinnecker GH, Hiort O. Phenotypic diversity and testosterone-induced normalization of mutant L712F androgen receptor function in a kindred with androgen insensitivity. J Clin Endocrinol Metab 2000;85:3245–50.Search in Google Scholar
7. Weidemann W, Peters B, Romalo G, Spindler KD, Schweikert HU. Response to androgen treatment in a patient with partial androgen insensitivity and a mutation in the deoxyribonucleic acid-binding domain of the androgen receptor. J Clin Endocrinol Metab 1998;83:1173–6.Search in Google Scholar
8. Dougan GC, Uli N, Shulman DI. Progressive central puberty in a toddler with partial androgen insensitivity. J Pediatr 2014;164:655–7.10.1016/j.jpeds.2013.11.020Search in Google Scholar
9. Hellmann P, Christiansen P, Johannsen TH, Main KM, Duno M, et al. Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Arch Dis Child 2012;97:403–9.10.1136/archdischild-2011-300584Search in Google Scholar
10. Choi SK, Han SW, Kim DH, de Lignieres B. Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. J Urol 1993;150:657–60.10.1016/S0022-5347(17)35576-3Search in Google Scholar
11. Charmandari E, Dattani MT, Perry LA, Hindmarsh PC, Brook CG. Kinetics and effect of percutaneous administration of dihydrotestosterone in children. Horm Res 2001;56:177–81.10.1159/000048115Search in Google Scholar
12. Kaya C, Bektic J, Radmayr C, Schwentner C, Bartsch G, et al. The efficacy of dihydrotestosterone transdermal gel before primary hypospadias surgery: a prospective, controlled, randomized study. J Urol 2008;179:684–8.10.1016/j.juro.2007.09.098Search in Google Scholar
13. Foresta C, Bettella A, Ferlin A, Garolla A, Moro E, et al. Response to local dihydrotestosterone treatment in a patient with partial androgen-insensitivity syndrome due to a novel mutation in the androgen receptor gene. Am J Med Genet 2002;107:259–60.10.1002/ajmg.10146Search in Google Scholar PubMed
14. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Res 1995;16:271–321.10.1210/edrv-16-3-271Search in Google Scholar PubMed
15. Veale D, Miles S, Bramley S, Muir G, Hodsoll J. Am I normal? A systematic review and construction of nomograms for flaccid and erect penis length and circumference in up to 15 521 men. BJU International 2015;115:978–86.10.1111/bju.13010Search in Google Scholar PubMed
16. Tomova A, Deepinder F, Robeva R, Lalabonova H, Kumanov P, et al. Growth and development of male external genitalia: a cross-sectional study of 6200 males aged 0 to 19 years. Arch Pediatr Adolesc Med 2010;164:1152–7.10.1001/archpediatrics.2010.223Search in Google Scholar PubMed
17. van den Driesche S, Scott HM, MacLeod DJ, Fisken M, Walker M, et al. Relative importance of prenatal and postnatal androgen action in determining growth of the penis and anogenital distance in the rat before, during and after puberty. Int J Androl 2011;34:e578–86.10.1111/j.1365-2605.2011.01175.xSearch in Google Scholar PubMed
18. Macleod DJ, Sharpe RM, Welsh M, Fisken M, Scott HM, et al. Androgen action in the masculinization programming window and development of male reproductive organs. Int J Androl 2010;33:279–87.10.1111/j.1365-2605.2009.01005.xSearch in Google Scholar PubMed
19. Welsh M, MacLeod DJ, Walker M, Smith LB, Sharpe RM. Critical androgen-sensitive periods of rat penis and clitoris development. Int J Androl 2010;33:e144–52.10.1111/j.1365-2605.2009.00978.xSearch in Google Scholar PubMed PubMed Central
20. Patel A, Rivkees SA. Prenatal virilization associated with paternal testosterone gel therapy. Int J Pediatr Endocrinol 2010;2010:867471.10.1186/1687-9856-2010-867471Search in Google Scholar
21. Lee PA, Houk CP. Outcome studies among men with micropenis. J Pediatr Endocrinol Metab 2004;17:1043–53.Search in Google Scholar
22. Money J, Lehne GK, Pierre-Jerome F. Micropenis: adult follow-up and comparison of size against new norms. J Sex Marital Ther 1984;10:105–16.10.1080/00926238408405796Search in Google Scholar PubMed
©2016 by De Gruyter
